Article Text
Statistics from Altmetric.com
The increase in the number and effectiveness of anticancer drugs has lengthened patients’ overall survival (OS) and simultaneously prolonged their time spent on treatment.1 This has led healthcare professionals to question the proportionality of care, particularly regarding when to suspend treatments that would be detrimental to the patient’s quality of life.2 3 The main publications on treatment break in cancer are in colorectal cancers or concerning immunotherapy.4 5
We report here the rate of treatment breaks in our cancer care unit, to assess the reality of this practice. We also aimed to characterise those breaks: the type of cancers involved and patients’ clinical outcomes (break duration, OS).
We screened 700 successive medical oncology consults from 2 December 2019 to 31 January 2020. These visits included breast, gynaecological, urological, brain, thyroid cancers and sarcomas, while excluding digestive, dermatological, cervicofacial and pulmonary cancers (as these are managed in other clinical units at our institution). We included only palliative care patients. We compared patient characteristics between those who experienced a short break (≤3 months) and those who had a long break (≥12 months) in search of predictive factors of long breaks. Statistical analyses were performed using SPSS V.26, and a p value<0.05 was considered statistically significant. This study was declared to the CNIL (National Commission for Data Protection).
We …
Footnotes
X @matcancel
Contributors FV initiated the project, collected, cleaned and analysed the data, drafted and revised the paper. FC designed the study, drafted and revised the paper. CL analysed the data, and revised the paper. DM designed the study, drafted and revised the paper. MC monitored data collection, analysed the data and drafted and revised the draft paper.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.